DK1383526T3 - Immuniseringsterapi til behandling af aterosklerose - Google Patents

Immuniseringsterapi til behandling af aterosklerose

Info

Publication number
DK1383526T3
DK1383526T3 DK02714667T DK02714667T DK1383526T3 DK 1383526 T3 DK1383526 T3 DK 1383526T3 DK 02714667 T DK02714667 T DK 02714667T DK 02714667 T DK02714667 T DK 02714667T DK 1383526 T3 DK1383526 T3 DK 1383526T3
Authority
DK
Denmark
Prior art keywords
treatment
atherosclerosis
immunization therapy
cardiovascular diseases
peptides
Prior art date
Application number
DK02714667T
Other languages
Danish (da)
English (en)
Inventor
Prediman K Shah
Jan Nilsson
Original Assignee
Forskarpatent I Syd Ab
Cedars Sinai Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0101232A external-priority patent/SE0101232D0/xx
Application filed by Forskarpatent I Syd Ab, Cedars Sinai Medical Center filed Critical Forskarpatent I Syd Ab
Application granted granted Critical
Publication of DK1383526T3 publication Critical patent/DK1383526T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
DK02714667T 2001-04-05 2002-04-05 Immuniseringsterapi til behandling af aterosklerose DK1383526T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0101232A SE0101232D0 (sv) 2001-04-05 2001-04-05 Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based elisa for determination of immune responses against oxidized low density liprotein
SE0103754A SE0103754L (sv) 2001-04-05 2001-11-09 Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
PCT/SE2002/000679 WO2002080954A1 (fr) 2001-04-05 2002-04-05 Therapie d'immunisation a base de peptides destinee au traitement d'atherosclerose et developpement d'un dosage a base de peptides permettant de determiner des reponses immunitaires contre la lipoproteine faible densite oxydee

Publications (1)

Publication Number Publication Date
DK1383526T3 true DK1383526T3 (da) 2009-03-30

Family

ID=26655437

Family Applications (3)

Application Number Title Priority Date Filing Date
DK02714667T DK1383526T3 (da) 2001-04-05 2002-04-05 Immuniseringsterapi til behandling af aterosklerose
DK10181267.5T DK2295464T3 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for the treatment of atherosclerosis targeting ApoB100
DK08151489.5T DK2006301T3 (da) 2001-04-05 2002-04-05 Peptid-baseret immuniseringsterapi til behandling af atherosklerose

Family Applications After (2)

Application Number Title Priority Date Filing Date
DK10181267.5T DK2295464T3 (en) 2001-04-05 2002-04-05 Peptide-based immunization therapy for the treatment of atherosclerosis targeting ApoB100
DK08151489.5T DK2006301T3 (da) 2001-04-05 2002-04-05 Peptid-baseret immuniseringsterapi til behandling af atherosklerose

Country Status (18)

Country Link
EP (42) EP2289928A1 (fr)
JP (6) JP2004529143A (fr)
CN (4) CN103122031B (fr)
AT (2) ATE510851T1 (fr)
AU (1) AU2002246484B8 (fr)
BR (1) BR0208685A (fr)
CA (3) CA2443223C (fr)
CY (1) CY1108817T1 (fr)
DE (1) DE60230029D1 (fr)
DK (3) DK1383526T3 (fr)
EE (2) EE200700052A (fr)
ES (2) ES2546293T3 (fr)
IL (4) IL158285A0 (fr)
PL (4) PL400308A1 (fr)
PT (1) PT1383526E (fr)
RU (1) RU2296582C2 (fr)
SE (1) SE0103754L (fr)
WO (1) WO2002080954A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105003A1 (en) 2001-04-05 2003-06-05 Jan Nilsson Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
PL372925A1 (en) 2001-09-28 2005-08-08 Esperion Therapeutics Inc. Prevention and treatment of restenosis by local administration of drug
SE0302312D0 (sv) 2002-10-04 2003-08-27 Forskarpatent I Syd Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
AU2003267905B2 (en) * 2002-10-04 2009-02-05 Biolnvent International Ab Peptide-based passive immunization therapy for treatment of atherosclerosis
SE0302422D0 (sv) * 2003-09-11 2003-09-11 Forskarpatent I Syd Ab Peptide-based immunization therapy for treatment of atherosclerosis
SE0400683D0 (sv) * 2004-03-19 2004-03-19 Forskarpatent I Syd Ab Use of modified extracellular matrix proteins in diagnosis and treatment of a atherosclerosis
US8926958B2 (en) 2004-04-06 2015-01-06 Cedars-Sinai Medical Center Prevention and treatment of vascular disease with recombinant adeno-associated virus vectors encoding apolipoprotein A-I and apolipoprotein A-I milano
CA2562550C (fr) * 2004-04-15 2013-09-24 Athera Biotechnologies Ab Conjugues de la phosphorylcholine et anticorps correspondants
EP1676602A1 (fr) * 2005-01-04 2006-07-05 Institut National De La Sante Et De La Recherche Medicale (Inserm) Administration continue d'épitopes derivés de protéinse présentes dans la plaque atèrosclérotique pour le traitement de l'athérosclérose
GB0517878D0 (en) 2005-09-02 2005-10-12 Bioinvent Int Ab Immunotherapeutic treatment
BRPI0720215A2 (pt) * 2006-12-22 2013-12-24 Abbott Lab Painel de doença autoimune cardiovascular e métodos de usar o mesmo.
WO2008104194A1 (fr) * 2007-02-28 2008-09-04 Bioinvent International Ab Lipoprotéines de basse densité oxyde et leurs anticorps pour le traitement de plaques d'athérosclérose
PE20090188A1 (es) 2007-03-15 2009-03-20 Novartis Ag Compuestos heterociclicos como moduladores de la senda de hedgehog
EP2538221A3 (fr) * 2007-11-05 2013-04-24 Nordic Bioscience A/S Marqueurs biochimiques pour évaluation de risque CVD
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP2319924B1 (fr) * 2008-08-15 2016-03-09 Fujikura Kasei Co., Ltd. Marqueur polypeptidique pour le diagnostic de l'artériosclérose, procédé de détection de l'artériosclérose à l'aide du marqueur ou similaire, et trousse de diagnostic de l'artériosclérose
AU2010319323B2 (en) 2009-11-14 2015-01-15 Cardiovax, Llc Immunomodulatory methods and systems for treatment and/or prevention of atherosclerosis
US8506964B2 (en) * 2010-02-05 2013-08-13 Cardiovax, Llc Fusion proteins and related compositions, methods and systems for treatment and/or prevention of atherosclerosis
WO2012024309A2 (fr) 2010-08-18 2012-02-23 Cedars-Sinai Medical Center Inhibition de l'athérosclérose par le biais de la modulation du phénotype des monocytes-macrophages en utilisant le transfert du gène apo a-i milano
RU2013126888A (ru) * 2010-11-12 2014-12-20 Седарс-Синаи Медикал Сентер ИММУНОМОДУЛИРУЮЩИЕ КОМПОЗИЦИИ, СПОСОБЫ И СИСТЕМЫ, СОДЕРЖАЩИЕ ИММУНОГЕННЫЕ ФРАГМЕНТЫ АроВ100
JP2013544243A (ja) 2010-11-12 2013-12-12 シーダース シナイ メディカル センター 動脈瘤の治療及び／又は予防のための免疫調節方法及びシステム
JP2014516913A (ja) 2010-11-12 2014-07-17 シーダース シナイ メディカル センター 高血圧の治療及び／又は予防のための免疫調節方法及びシステム
JP6277126B2 (ja) 2011-08-09 2018-02-07 アセラ・バイオテクノロジーズ・アーベー ホスホリルコリン（ｐｃ）および／またはｐｃコンジュゲートに結合する抗体
JP6277125B2 (ja) 2011-08-09 2018-02-07 アセラ・バイオテクノロジーズ・アーベー ホスホリルコリンに対する新規抗体
RU2495048C1 (ru) * 2012-04-18 2013-10-10 Андрей Валентинович Исаев Пептид, обладающий антиатеросклеротическим действием и композиция для профилактики и лечения атеросклероза сосудов
EP2917234B1 (fr) * 2012-11-06 2020-12-02 Les Hôpitaux Universitaires de Genève Peptides mimétiques
CN103520713B (zh) * 2013-10-16 2015-10-28 西北农林科技大学 一种ApoB100酵母重组疫苗及其制备方法和应用
CN103860470A (zh) * 2014-03-05 2014-06-18 贵州中泰生物科技有限公司 一种口服高密度脂蛋白脂质体的制备方法
CN105315364B (zh) * 2014-06-17 2018-09-18 广州文瑞生物科技有限公司 胶原蛋白vi疫苗预防动脉粥样硬化
EP3297652A4 (fr) * 2015-05-19 2019-06-05 La Jolla Institute for Allergy and Immunology Épitopes apob100 humains, méthodes et utilisations pour moduler des réponses inflammatoires et traiter des événements cardiovasculaires défavorables, la maladie cardiovasculaire et l'athérosclérose
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
CN108478817B (zh) * 2018-03-16 2020-10-27 北京大学 一种动脉粥样硬化检测试剂及其制备方法
WO2019232081A1 (fr) 2018-05-29 2019-12-05 Abcentra, Llc Compositions et procédés pour le traitement de la polyarthrite rhumatoïde et de l'athérosclérose accélérée

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970144A (en) 1984-12-31 1990-11-13 International Genetic Engineering Peptide fragments of human apolipoprotein, type-specific antibodies and methods of use
US5972890A (en) 1988-05-02 1999-10-26 New England Deaconess Hospital Corporation Synthetic peptides for arterial imaging
WO1993018067A1 (fr) * 1992-03-06 1993-09-16 Abbott Laboratories Dosage par immunocapture pour quantification directe de niveaux de cholesterol de lipoproteines specifiques
WO1994000592A1 (fr) * 1992-06-26 1994-01-06 Exocell, Inc. Anticorps monoclonaux agissant contre des lipoproteines glycatees de faible densite
EP0671926B1 (fr) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Peptides immunomodulateurs
KR0185334B1 (ko) 1995-11-02 1999-04-01 김은영 인간 혈장 아포지단백질 비-100에 결합하는 생쥐 항체를 암호하는 씨디엔에이
GB9609702D0 (en) * 1996-05-09 1996-07-10 Royal Free Hosp School Med Anticoagulant peptides
GB9620153D0 (en) * 1996-09-27 1996-11-13 Univ Strathclyde Non-naturally occurring lipoprotein particle
GB9705831D0 (en) * 1997-03-20 1997-05-07 Univ Leicester Oxidised ldl
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6225070B1 (en) 1997-08-07 2001-05-01 The Regents Of The University Of California Antibodies to oxidation-specific epitopes on lipoprotein and methods for their use in detecting, monitoring and inhibiting the growth of atheroma
US6156315A (en) * 1997-10-10 2000-12-05 The Trustees Of Columbia University In The City Of New York Method for inhibiting the binding of low density lipoprotein to blood vessel matrix
EP0911344B1 (fr) * 1997-10-15 2004-03-03 Fujirebio Inc. Anticorps monoclonal contre l'Apo B-48, hybridome et procédés d'utilisation
CA2323056A1 (fr) * 1998-03-10 1999-09-16 Regents Of The University Of California Procedes et outils utilises pour identifier des composes qui modulent l'atherosclerose par alteration de la liaison ldl-proteoglycane
AU5200699A (en) * 1998-07-13 2000-02-01 University Of Otago Inhibition of lipoprotein formation
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
AU773370B2 (en) * 1999-10-26 2004-05-20 Regents Of The University Of California, The Reagents and methods for diagnosing, imaging and treating atherosclerotic disease
AU2001236589A1 (en) * 2000-02-04 2001-08-14 Aeomica, Inc. Methods and apparatus for high-throughput detection and characterization of alternatively spliced genes
IL151355A0 (en) * 2000-03-03 2003-04-10 Smithkline Beecham Biolog Vaccine for the treatment of artherosclerosis
SE0000855D0 (sv) * 2000-03-15 2000-03-15 Karolinska Innovations Ab Antigenic composition useful as a vaccine against atherosclerosis
GB0017641D0 (en) * 2000-07-18 2000-09-06 Medigene Oy Peptides and their use
EP1186299A1 (fr) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht Diagnostic, prévention et/ou traitement d' athérosclérose, infections et perturbations du système immunitaire
JP2004529080A (ja) * 2000-10-25 2004-09-24 アグネッロ，ヴィンセント Ｈｃｖ、他のフラビウイルス科ウイルス、および血液中で低密度リポタンパク質または超低密度リポタンパク質と複合体を形成するその他のあらゆるウイルスによる感染を細胞中へのウイルス侵入を抑制することによって防止する方法
AU2002241603A1 (en) * 2000-11-10 2002-06-03 University Of Utah Research Foundation Carrier system for specific artery wall gene delivery
SE0103754L (sv) * 2001-04-05 2002-10-06 Forskarpatent I Syd Ab Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid
US7241861B2 (en) * 2001-05-15 2007-07-10 Japan Immunoresearch Laboratories Co., Ltd. High density lipoprotein-reactive peptides
WO2003007689A2 (fr) * 2001-07-20 2003-01-30 Eidgenoessische Technische Hochschule Zurich (Ethz) Compositions et procedes pour l'utilisation d'agents bioactifs derives d'acides sulfates et sulfones

Also Published As

Publication number Publication date
DK2295464T3 (en) 2015-08-17
EP1383526B1 (fr) 2008-11-26
EP2289927A1 (fr) 2011-03-02
WO2002080954A1 (fr) 2002-10-17
EP2289926A1 (fr) 2011-03-02
EP2289922A1 (fr) 2011-03-02
CN101284874A (zh) 2008-10-15
EP2289932A1 (fr) 2011-03-02
CY1108817T1 (el) 2014-04-09
EP2305706A1 (fr) 2011-04-06
PL367301A1 (en) 2005-02-21
JP2011063598A (ja) 2011-03-31
EP2295464B1 (fr) 2015-06-03
EP2147930A3 (fr) 2010-04-14
EP2305708A1 (fr) 2011-04-06
EP2289928A1 (fr) 2011-03-02
EP2289916A1 (fr) 2011-03-02
ATE415423T1 (de) 2008-12-15
ATE510851T1 (de) 2011-06-15
EP2289933A1 (fr) 2011-03-02
DK2006301T3 (da) 2011-09-12
EP2289913A1 (fr) 2011-03-02
EP2295460B1 (fr) 2015-06-03
EP2289924A1 (fr) 2011-03-02
CA2443223C (fr) 2013-11-26
EP2289921A1 (fr) 2011-03-02
EP2289931A1 (fr) 2011-03-02
CN103122031A (zh) 2013-05-29
EP2289923A1 (fr) 2011-03-02
EP2289934B1 (fr) 2013-11-13
EP1918300A2 (fr) 2008-05-07
PT1383526E (pt) 2009-02-27
EP2289930A1 (fr) 2011-03-02
IL188286A0 (en) 2008-03-20
EP2295463A1 (fr) 2011-03-16
EP2295458A1 (fr) 2011-03-16
AU2002246484A1 (en) 2002-10-21
CN103122031B (zh) 2015-07-22
CA2827167A1 (fr) 2002-10-17
EP2289925A1 (fr) 2011-03-02
ES2317999T3 (es) 2009-05-01
EP2147680A3 (fr) 2010-04-14
EP1918300A3 (fr) 2009-06-17
EP2289918A1 (fr) 2011-03-02
JP2004529143A (ja) 2004-09-24
EP2147680A2 (fr) 2010-01-27
AU2002246484B8 (en) 2007-06-14
EP2295464A1 (fr) 2011-03-16
SE0103754L (sv) 2002-10-06
EP2147929A3 (fr) 2010-04-14
JP2011068654A (ja) 2011-04-07
EP2147929A2 (fr) 2010-01-27
EP2289934A1 (fr) 2011-03-02
DE60230029D1 (de) 2009-01-08
EE200700052A (et) 2008-08-15
EP2289929A1 (fr) 2011-03-02
JP5300820B2 (ja) 2013-09-25
EP2289914A1 (fr) 2011-03-02
JP2008169215A (ja) 2008-07-24
PL217858B1 (pl) 2014-08-29
EP2295462A1 (fr) 2011-03-16
RU2003132443A (ru) 2005-02-27
SE0103754D0 (sv) 2001-11-09
IL158285A0 (en) 2004-05-12
PL400308A1 (pl) 2012-12-17
IL195356A0 (en) 2009-08-03
CN1505525A (zh) 2004-06-16
EP2289917A1 (fr) 2011-03-02
PL215401B1 (pl) 2013-12-31
IL158285A (en) 2009-12-24
EP2147928A2 (fr) 2010-01-27
RU2296582C2 (ru) 2007-04-10
EP2289912A1 (fr) 2011-03-02
JP5300819B2 (ja) 2013-09-25
EE200300487A (et) 2004-02-16
JP2009191078A (ja) 2009-08-27
JP5270456B2 (ja) 2013-08-21
CA2443223A1 (fr) 2002-10-17
EP2147928A3 (fr) 2010-04-14
BR0208685A (pt) 2004-03-30
EP2289935A1 (fr) 2011-03-02
CN1505525B (zh) 2012-11-07
EP2295461A1 (fr) 2011-03-16
EP2006301B1 (fr) 2011-05-25
EP2305707A1 (fr) 2011-04-06
AU2002246484B2 (en) 2007-04-19
EP2295457A1 (fr) 2011-03-16
CN101486766A (zh) 2009-07-22
CN101284874B (zh) 2012-10-03
JP2013144687A (ja) 2013-07-25
EP2147930A2 (fr) 2010-01-27
CA2606839A1 (fr) 2002-10-17
ES2546293T3 (es) 2015-09-22
EP2289919A1 (fr) 2011-03-02
EP2006301A1 (fr) 2008-12-24
EP2295460A1 (fr) 2011-03-16
CA2606839C (fr) 2015-06-09
JP5613890B2 (ja) 2014-10-29
EP1383526A1 (fr) 2004-01-28
EP2289920A1 (fr) 2011-03-02
EP2295459A1 (fr) 2011-03-16
EP2289915A1 (fr) 2011-03-02

Similar Documents

Publication Publication Date Title
DK1383526T3 (da) Immuniseringsterapi til behandling af aterosklerose
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
CY1112229T1 (el) Αντισωματα κατευθυνομενα εναντι οξειδωμενης απολιποπρωτεϊνης β
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
SE0401601D0 (sv) Protofibril specific antibodies and uses thereof
ATE549347T1 (de) Gene von säugetiere, und damit verbundene reagentien, methoden
DE69738138D1 (de) Induktion von immunologischer Toleranz gegen einen therapeutischen Antikörper durch Varianten des therapeutischen Antikörpers
EA200801174A1 (ru) Антитела-миметики glp-2, полипептиды, композиции, способы и применения
DE602004028592D1 (de) Gegen clostridium difficile gerichtete antikörper
HK1088909A1 (en) Peptide-based immunization therapy for treatment of atherosclerosis
DK1374895T3 (da) Farmaceutisk sammensætning af F(AB) 2-fragmenter af antistoffer og fremgangsmåde til fremstilling heraf
WO2004030607A3 (fr) Therapie d'immunisation passive a base peptidique pour le traitement de l'atherosclerose
SE0202959D0 (sv) Peptide-Base passive immunization therapy for treatment of atherosclerosis
DK1275638T3 (da) Kombinationspræparat til behandling af immunologiske sygdomme
BRPI0216033B8 (pt) "terapia de imunização à base de peptídio para tratamento de arteriosclerose"
FR2839721B1 (fr) Antigene polypeptidique induisant des anticorps neutralisant le vih
SE0203226D0 (sv) Immunoglobulin bindning site
ITTO20010795A0 (it) Polipeptide isolato basato sulla sequenza della proteina p17 utile come vaccino anti-hiv.